1. Home
  2. CRBP vs FEAM Comparison

CRBP vs FEAM Comparison

Compare CRBP & FEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRBP
  • FEAM
  • Stock Information
  • Founded
  • CRBP 2009
  • FEAM 2016
  • Country
  • CRBP United States
  • FEAM United States
  • Employees
  • CRBP N/A
  • FEAM N/A
  • Industry
  • CRBP Biotechnology: Pharmaceutical Preparations
  • FEAM Major Chemicals
  • Sector
  • CRBP Health Care
  • FEAM Industrials
  • Exchange
  • CRBP Nasdaq
  • FEAM Nasdaq
  • Market Cap
  • CRBP 110.3M
  • FEAM 94.7M
  • IPO Year
  • CRBP N/A
  • FEAM N/A
  • Fundamental
  • Price
  • CRBP $9.79
  • FEAM $3.49
  • Analyst Decision
  • CRBP Strong Buy
  • FEAM Strong Buy
  • Analyst Count
  • CRBP 10
  • FEAM 2
  • Target Price
  • CRBP $53.22
  • FEAM $121.00
  • AVG Volume (30 Days)
  • CRBP 107.9K
  • FEAM 58.7K
  • Earning Date
  • CRBP 08-05-2025
  • FEAM 09-03-2025
  • Dividend Yield
  • CRBP N/A
  • FEAM N/A
  • EPS Growth
  • CRBP N/A
  • FEAM N/A
  • EPS
  • CRBP N/A
  • FEAM N/A
  • Revenue
  • CRBP N/A
  • FEAM N/A
  • Revenue This Year
  • CRBP N/A
  • FEAM N/A
  • Revenue Next Year
  • CRBP $270.04
  • FEAM N/A
  • P/E Ratio
  • CRBP N/A
  • FEAM N/A
  • Revenue Growth
  • CRBP N/A
  • FEAM N/A
  • 52 Week Low
  • CRBP $4.64
  • FEAM $2.82
  • 52 Week High
  • CRBP $61.89
  • FEAM $24.84
  • Technical
  • Relative Strength Index (RSI)
  • CRBP 62.32
  • FEAM 42.97
  • Support Level
  • CRBP $8.88
  • FEAM $4.22
  • Resistance Level
  • CRBP $9.59
  • FEAM $4.73
  • Average True Range (ATR)
  • CRBP 0.59
  • FEAM 0.44
  • MACD
  • CRBP 0.03
  • FEAM -0.03
  • Stochastic Oscillator
  • CRBP 78.45
  • FEAM 13.24

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About FEAM 5E Advanced Materials Inc.

5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.

Share on Social Networks: